This HTML5 document contains 59 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n11http://localhost/temp/predkladatel/
n16http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n15http://linked.opendata.cz/resource/domain/vavai/projekt/
n17http://linked.opendata.cz/ontology/domain/vavai/
n10http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
n12http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F61989592%3A15110%2F06%3A00003101%21RIV09-MZ0-15110___/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n19http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n13http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n7http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F61989592%3A15110%2F06%3A00003101%21RIV09-MZ0-15110___
rdf:type
skos:Concept n17:Vysledek
dcterms:description
Hematologic toxicity is reported as one of the most important problems connected with imatinib mesylate (IM) treatment in patients with chronic myelogenous leukemia (CML). Withholding the drug or application of growth factors is recommended in this situation. This study introduced a novel approach using intermittent dosage of IM in order to avoid prolonged interruptions in therapy, to allow spontaneous recovery in blood count and, simultaneously, to achieve intermittently therapeutic plasma drug levels. A retrospective analysis of intermittent therapy (iT) in 12 patients with CML is presented. All patients had intermediate-to-high prognostic scores. Two patients had history of autologous stem cell transplantation. Initial standard therapy with IM was indicated for resistance to interferon (eight subjects) and for accelerated phase in four cases (one of them cytogenetic) and lasted for 1 - 6 months. iT with 300 - 600 mg of IM 1 - 5 times a week was started after significant hematologic toxicity occurre Hematologic toxicity is reported as one of the most important problems connected with imatinib mesylate (IM) treatment in patients with chronic myelogenous leukemia (CML). Withholding the drug or application of growth factors is recommended in this situation. This study introduced a novel approach using intermittent dosage of IM in order to avoid prolonged interruptions in therapy, to allow spontaneous recovery in blood count and, simultaneously, to achieve intermittently therapeutic plasma drug levels. A retrospective analysis of intermittent therapy (iT) in 12 patients with CML is presented. All patients had intermediate-to-high prognostic scores. Two patients had history of autologous stem cell transplantation. Initial standard therapy with IM was indicated for resistance to interferon (eight subjects) and for accelerated phase in four cases (one of them cytogenetic) and lasted for 1 - 6 months. iT with 300 - 600 mg of IM 1 - 5 times a week was started after significant hematologic toxicity occurre Hematologická toxicita je jedním z nejvýzamnějších problémů při léčbě chronické myeloidní leukemie pomocí imatinib mesylátu (IM). V této situaci je doporučováno vysazení léku nebo aplikace růstových faktorů. Tato studie uvádí nový přístup spočívající ve využití přerušovaného podávání IM ...
dcterms:title
Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing Přerušované dávkování imatinibu u CML pacientů se signifikantní hematologickou toxicitou po standardním dávkování
skos:prefLabel
Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing Přerušované dávkování imatinibu u CML pacientů se signifikantní hematologickou toxicitou po standardním dávkování Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing
skos:notation
RIV/61989592:15110/06:00003101!RIV09-MZ0-15110___
n3:aktivita
n8:P n8:Z
n3:aktivity
P(GA301/04/1239), P(NR7870), Z(MSM6198959205)
n3:cisloPeriodika
6
n3:dodaniDat
n7:2009
n3:domaciTvurceVysledku
n16:3461904 n16:2556049 n16:2328356 n16:8478325 n16:8141975 n16:8539855 n16:8227659
n3:druhVysledku
n9:J
n3:duvernostUdaju
n19:S
n3:entitaPredkladatele
n12:predkladatel
n3:idSjednocenehoVysledku
480111
n3:idVysledku
RIV/61989592:15110/06:00003101
n3:jazykVysledku
n13:eng
n3:klicovaSlova
chronic myelogenous leukemia; CML; imatinib mesylate; intemittent therapy; Bcr/Abl
n3:klicoveSlovo
n4:CML n4:imatinib%20mesylate n4:intemittent%20therapy n4:chronic%20myelogenous%20leukemia n4:Bcr%2FAbl
n3:kodStatuVydavatele
GB - Spojené království Velké Británie a Severního Irska
n3:kontrolniKodProRIV
[23D8E7BAB831]
n3:nazevZdroje
Leukemia & lymphoma
n3:obor
n18:FD
n3:pocetDomacichTvurcuVysledku
7
n3:pocetTvurcuVysledku
9
n3:projekt
n15:GA301%2F04%2F1239 n15:NR7870
n3:rokUplatneniVysledku
n7:2006
n3:svazekPeriodika
47
n3:tvurceVysledku
Divoký, Vladimír Veselovská, Jitka Egorin, Merrill J. Jarošová, Marie Faber, Edgar Indrák, Karel Rožmanová, Šárka Holzerová, Milena Marešová, Ivana
n3:zamer
n10:MSM6198959205
s:issn
1042-8194
s:numberOfPages
9
n11:organizacniJednotka
15110